(12.03.2020)

Last Monday, Menichella was among the top executives of nearly a dozen biotech and pharmaceutical companies briefing President Trump on their respective coronavirus drug development plans. Just over a week later, he was out as CEO, replaced by CureVac founder and former CEO Hoerr.

It‘s a rapid transition in leadership at a time when the company is in the global spotlight for its efforts to quickly advance a coronavirus vaccine into human testing.